Redeye provides an initial take on the FDA notification for BONESUPPORT’s De Novo application for CERAMENT G (osteomyelitis indication). Off the bat, the FDA announcement is, of course, negative – especially from a shorter-term sales perspective. However, after discussions with management and initial reviews of our sales and cost estimates, we remain confident in our view of BONESUPPORT as an attractive long-term play on high sales growth and significant operating leverage.